Neumora Therapeutics reports data from KOASTAL-1 study of navacaprant in major depressive disorder
- The KOASTAL-1 study did not show statistically significant improvement in depressive symptoms with navacaprant compared to placebo.
- An efficacy signal was observed in female participants, prompting further analysis by the company.
- Navacaprant was generally well-tolerated, with a safety profile similar to placebo and no serious adverse events reported.
- Neumora plans to provide additional updates on the navacaprant development program at the J.P. Morgan Healthcare Conference.
Read more
